GlassScriptPhysician profile
Clark W Antonson
NPI 1831182757
$4,082.14
in general payments reported to CMS, 2019-2025
27 companies · $585 in 2025
The $585 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $324 · 2021: $364 · 2022: $264 · 2023: $556 · 2024: $1,623 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283 · Travel and Lodging: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.94 |
| Travel and Lodging | $481.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,346.17 | 2019-2025 | Exalt Model D, Spyglass, Axios |
| Aimmune Therapeutics, INC. | $513.96 | 2024 | |
| Abbvie INC. | $405.15 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $222.94 | 2020-2025 | Stelara, Tremfya |
| Genzyme Corporation | $185.35 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $162.29 | 2022-2023 | Stelara |
| Nestle Healthcare Nutrition INC. | $148.47 | 2021-2023 | |
| Olympus America INC. | $142.62 | 2019-2020 | |
| Gilead Sciences, INC. | $134.06 | 2020-2025 | |
| Lilly USA, LLC | $104.85 | 2024-2025 | Omvoh |
| Celgene Corporation | $100.01 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $98.38 | 2025 | Iqirvo |
| Amgen INC. | $84.13 | 2021-2025 | Uplizna, Amjevita, Avsola |
| Takeda Pharmaceuticals U.S.A., INC. | $71.61 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $70.72 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.74 | 2022-2023 | Dupixent |
| Madrigal Pharmaceuticals | $43.42 | 2024-2025 | Resmetirom, Rezdiffra |
| Daiichi Sankyo INC. | $42.76 | 2022-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.40 | 2020-2024 | Xifaxan |
| Allergan, INC. | $18.64 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.06 | 2022 | |
| Intercept Pharmaceuticals, INC. | $15.84 | 2024 | |
| Qol Medical, LLC | $14.72 | 2020 | |
| Ucb, INC. | $14.31 | 2024 | Cimzia |
| Ironwood Pharmaceuticals, INC | $12.01 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 | |
| Phathom Pharmaceuticals, INC. | $9.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clark Antonson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.